Evaluation of efficiency of tactics to improve the preterm birth results (review)

Bibliography:
1. Berger R, Abele H, Bahlmann F, et al. Prevention and therapy of preterm birth: Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry Number 015/025, February 2019): Part 1 with recommendations on the epidemiology etiology, prediction, primary and secondary prevention of preterm birth. Geburtshilfe Frauenheilkd 2019; 79 (8): 800-12. DOI: 10.1055/a-0903-2671.
2. American College of Obstetricians and Gynecologists' Committee on practice bulletins-obstetrics: Practice bulletin No. 171: Management of preterm labor. Obstet Gynecol 2016; 128 (4): 155-64. DOI: 10.1097/AOG. 0000000000001711.
3. Rundell K, Panchal B. Preterm labor: prevention and management. Am Fam Physician 2017; 95 (6): 366-72.
4. Haram K, Mortensen JH, Magann EF, et al. Antenatal corticosteroid treatment: factors other than lung maturation. J Matern Fetal Neonatal Med 2017; 30 (12): 1437-41. DOI: 10.108 0/14767058.2016.1219716. Epub 2016 Aug 30.
5. American College of Obstetricians and Gynecologists: Antenatal corticosteroid therapy for fetal maturation: Committee opinion No. 713. Obstet Gynecol 2017; 130: 102-9. URL: https:// www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Obstetric-Practice / Antenatal-Corticosteroid-Therapy-for-Fetal-Maturation.
6. LauHCQ, Tung JSZ, Wong TTC,etal. Timing of antenatal steroids exposure and its effects on neonates. Arch Gynec Obstet 2017; 296 (6): 1091-6. DOI: 10.1007/s00404-017-4543-1. Epub 2017Sep25.
7. Boutin SA, Bujold A, Burrows E, et al. No. 364-Antenatal corticosteroid therapy for improving neonatal outcomes. J Obstet Gynaecol Canada 2018; 40 (9): 1219-39. URL: https:// doi.org/10.1016/j. jogc. 2018.04.018.
8. Gyamfi-Bannerman C, Thorn EA, Blackwell SC, et al. Antenatal betamethasone for women at risk for late preterm delivery. N Engl J Med 2016; 374 (14): 1311-20. DOI: 10.1056/NEJMoa1516783.
9. Souter V, Kauffman E, Marshall AJ, et al. Assessing the potential impact of extending antenatal steroids to the late preterm period. Am J Obstet Gynecol 2017; 217 (4): 461-7. URL: https://doi.Org/10.1016/j. ajog. 2017.04.029.
10. Amiya RM, Mlunde LB, Ota E, et al. Antenatal corticosteroids for reducing adverse maternal and child outcomes in special populations of women at risk of imminent preterm birth: a systematic review and meta-analysis. PLoS ONE 2016; 11 (2): 0147604. URL: https://doi.org/10.1371/journal. pone. 0147604.
11. Schmitz T. Prevention of preterm birth complications by antenatal corticosteroid administration. J Gynecol Obstet Biol Reprod (Paris) 2016; 45 (10): 1399-417. DOI: 10.1016/j. jgyn. 2016.09.008. Epub 2016 Oct 21.
12. Lyon C, Bello JK. Steroids during late preterm labor: better later than never. J Fam Pract 2017; 66 (2): 104-6. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329115.
13. WHO recommendation on use of either dexamethasone or betamethasone as the antenatal corticosteroid of choice/The WHO Reproductive Health Library. Geneva: World Health Organization, 2015. URL: https:// extranet.who.int/rhl/topics/preconce ption-pregnancy-childbirth-a nd-post part um-ca re /pregnancy-corn plications / preterm- birth/who-recommendation-use-either-dexamethasone-or-betamethasone-antenatal-corticosteroid-choice.
14. WHO recommendation on use of a single repeat course of antenatal corticosteroid/The WHO Reproductive Health Library. Geneva: World Health Organization, 2015. URL: https:// extranet.who.int/rhl/topics/preconception-pregnancy-childbirth-and-postpartum-care /pregnancy-cornplications/preterm-birth/who-recommendation-use-single-repeat-course-antenatal-corticosteroid.
15. WHO recommendation on antenatal corticosteroid therapy in women undergoing planned caesarean section at late preterm gestations (34-36+6 weeks)/The WHO Reproductive Health Library. Geneva: World Health Organization, 2015. URL: https://extranet.who.int/rhl/topics/preconception-preg na n cy-ch i Id birth-a nd-post part um-ca re / pregnancy-complications/preterm-birth/who-recommendation-antenatal-corticosteroid-therapy-women-undergoing-planned-caesarean-section-late.
16. Doret M, Kayem G. Tocolysis for preterm labor without premature preterm rupture of membranes. J Gynecol Obstet Biol Reprod (Paris) 2016; 45 (10): 1374-98. DOI: 10.1016/j. jgyn. 2016.09.018. Epub 2016 Oct 28.
17. WHO recommendation on the use of tocolytic treatment for inhibiting preterm labour/The WHO Reproductive Health Library. Geneva: World Health Organization, 2015. URL: https:// extranet.who.int/rhl/topics/preconception-pregnancy-childbirth-and-postpartum-care /pregnancy-cornplications/preterm-birth/who-recommendation-use-tocolytic-treatment-inhibiting-preterm-labour).
18. Yoneda S, Yoneda N, Fukuta K, et al. In which preterm labor-patients is intravenous maintenance tocolysis effective? J Obstet Gynaecol Res 2018; 44: 397-407. DOI: 10.1111 /jog. 13547.
19. Morfaw F, Fundoh M, Bartoszko J, et al. Using tocolysis in pregnant women with symptomatic placenta praevia does not significantly improve prenatal, perinatal, neonatal and maternal outcomes: a systematic review and meta-analysis. Syst Rev 2018; 7 (1): 249. DOI: 10.1186/s13643-018-0923-2.
20. Ding MX, Luo X, Zhang XM, et al. Progesterone and nifedipine for maintenance tocolysis after arrested preterm labor: A systematic review and meta-analysis of randomized controlled trial. Taiwan J Obstet Gynecol 2016; 55 (3): 399-404. DOI: 10.1016/j. tjog. 2015.07.005.
21. Miyazaki C, Garcia RM, Ota E, et al. Tocolysis for inhibiting preterm birth in extremely preterm birth, multiple gestations and in growth-restricted fetuses: a systematic review and meta-analysis. Reproductive Health 2016; 13 (1): 1. URL: https://doi.Org/10.1186/s12978-015-0115-7.
22. Wood S, Rabi Y, Tang S, et al. Progesterone in women with arrested premature labor, a report of a randomised clinical trial and updated meta-analysis. ВМС Pregnancy Childbirth 2017; 17 (1): 258. DOI: 10.1186/s12884-017-1400-y.
23. Ohhashia M, Yoshitomib T, Sumiyoshia K, et al. Magnesium sulphate and perinatal mortality and morbidity in very-low-birthweight infants born between 24 and 32 weeks of gestation in Japan. European Journal of Obstetrics and Gynecology and Reproductive Biology 2016; 201: 140-5. URL: https://doi.Org/10.1016/j. ejogrb. 2016.03.048.
24. Shepherd E, Salam RA, Middleton P, et al. Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev 2017; 8 (8): CD012077. DOI: 10.1002/14651858. CD012077. pub2.
25. Brookfield KF, Elkomy M, Su F, et al. Optimization of maternal magnesium sulfate administration for fetal neuroprotection: application of a prospectively constructed pharmacokinetic model to the beam cohort. The Journal of Clinical Pharmacology 2017; 57 (11): 1419-24. DOI: 10.1002/jcph. 941.
26. Brookfield KF, Vinson A. Magnesium sulfate use for fetal neuroprotection. Curr Opin Obstet Gynecol 2019; 31 (2): 110-5. DOI: 10.1097/GCO. 0000000000000529.
27. Berger R, Su,der S. Neuroprotection in preterm infants. Biomed Res Int 2015; 2015:257139. DOI: 10.1155/2015/257139.
28. Zeng X, Xue Y, Tian Q, et al. Effects and safety of magnesium sulfate on neuroprotection: a meta-analysis based on prisma guidelines. Medicine (Baltimore) 2016; 95 (1): 2451. DOI: 10.1097/MD. 0000000000002451.
29. De Silva ML, Sawchuck DA, Synnes D, et al. No. 376-Magnesium sulphate for fetal neuroprotection. J Obstet and Gynaecol Can 2019; 419 (4): 505-22. URL: https:// doi.org/10.1016/j. jogc. 2018.09.018.
30. Marret S, Ancel P-Y. Protection cerebrale de I'enfant ne premature par le sulfate de magnesium. La Revue Sage-Femme 2017; 16 (4): 262-78. URL: https://doi.Org/10.1016/j. jgyn. 2016.09.028.
31. Bachnas AM, Akbar IAM, Dachlan GE, et al. The role of magnesium sulfate (MgS04) in fetal neuroprotection. J Matern Fetal Neonatal Med 2019; 15: 1-361. DOI: 10.1080/14767058.2 019.1619688.
32. Meller CH, Izbizky G, Otaco L. Update on the use of magnesium sulphate for fetal neuroprotection in preterm birth. Arch Argent Pediatr 2015; 113 (4): 345-51. DOI: 10.5546/aap. 2015.345.
33. Vilchez G, Dai J, Lagos M, et al. Maternal side effects & fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. J Matern Fetal Neonatal Med 2018; 31 (2): 178-83. DOI: 10.1080/ 14767058.2017.1279143. Epub 2017 Jan 23.
34. Doyle LW, Anderson PJ, Haslam R, et al. School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA 2014; 312 (11): 1105-13. DOI: 10.1001/jama. 2014.11189.
35. Thinkhamrop J, Hofmeyr GJ, Adetoro O, et al. Antibiotic prophylaxis during the second and third trimester to reduce adverse pregnancy outcomes and morbidity. Cochrane Database Syst Rev2015; 1: CD002250. DOI: 10.1002/14651858. CD002250. pub2.
36. Kayem G, Lorthe E, Doret M. Management of preterm labor. J Gynecol Obstet Biol Reprod (Paris) 2016; 45 (10): 1364-73. DOI: 10.1016/j. jgyn. 2016.09.029. Epub 2016 Oct 24.
37. Yoneda S, Shiozaki A, Yoneda N, et al. Antibiotic therapy increases the risk of preterm birth in preterm labor without intra-amniotic microbes, but may prolong the gestation period in preterm labor with microbes, evaluated by rapid and high-sensitive PCR system. Am J Reprod Immunol 2016; 75 (4): 440-50. DOI: 10.1111/aji. 12484. Epub 2016 Jan 18.
38. Brabant G. Bacterial vaginosis and spontaneous preterm birth. J Gynecol Obstet Biol Reprod (Paris) 2016; 45 (10): 1247-60. DOI: 10.1016/j. jgyn. 2016.09.014. Epub 2016 Oct 26.